Literature DB >> 8887262

Typical and atypical hemolytic uremic syndrome.

W Proesmans1.   

Abstract

The hemolytic uremic syndrome is the most frequent cause of acute renal failure in childhood. In the vast majority of patients, the syndrome of acute hemolysis, thrombopenia and renal dysfunction is preceded by an episode of diarrhea with or without bloody stools. This colitis is caused by different strains of Escherichia coli which produce shiga like toxins. These toxins are responsible for both hemolysis and renal disease. There are good reasons for distinguishing patients with D (+) HUS and those without prodromal diarrhea [D (-) HUS], especially since the outcome in the latter group is less predictable and on average fairly unfavorable. D (+) HUS has also been labeled 'typical HUS' and D (-) HUS as 'atypical HUS'. This has led to some oversimplification, in that atypical has become synonymous with poor outcome. Our experience comprises 20 D (-) HUS patients, of whom 14 did extremely well. Scrutinizing the data of our patients lead to the conclusion that, within the D (-) group, some have a 'typical course' and display complete cure whereas those with an 'atypical course' either die or have severe sequelae.

Entities:  

Mesh:

Year:  1996        PMID: 8887262     DOI: 10.1159/000174075

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  8 in total

1.  Atypical hemolytic-uremic syndrome (HUS) with recovery after a long-lasting anuria: a case report.

Authors:  H Georgaki-Angelaki; N Stergiou; A Kapogiannis; I Orfanou; B Grapsa; E Roma
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

2.  Haemolytic uraemic syndrome associated with gemcitabine.

Authors:  Irene Moya-Horno; Rosa Querol Niñerola; Teresa Bonfill Abella; Elsa Dalmau Pórtulas; Enrique Gallardo-Díaz; Eugeni Saigí Grau; Carles Pericay Pijaume
Journal:  Clin Transl Oncol       Date:  2010-05       Impact factor: 3.405

3.  A time for reappraisal of "atypical" hemolytic uremic syndrome: should all patients be treated the same?

Authors:  Rebecca L Ruebner; Bernard S Kaplan; Lawrence Copelovitch
Journal:  Eur J Pediatr       Date:  2012-06-07       Impact factor: 3.183

Review 4.  Pathogenesis of thrombotic microangiopathies.

Authors:  X Long Zheng; J Evan Sadler
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

Review 5.  Atypical hemolytic-uremic syndrome: a case report and literature review.

Authors:  Arsalan Rafiq; Hassan Tariq; Naeem Abbas; Roopalekha Shenoy
Journal:  Am J Case Rep       Date:  2015-02-24

6.  Haemolytic uraemic syndrome associated with H1N1 influenza.

Authors:  Ana Farinha; Patrícia Carrilho; Joana Felgueiras; Ana Natário; José Assunção; José Vinhas
Journal:  NDT Plus       Date:  2010-07-15

7.  The use of eculizumab in gemcitabine induced thrombotic microangiopathy.

Authors:  Vinod Krishnappa; Mohit Gupta; Haikoo Shah; Abhijit Das; Natthavat Tanphaichitr; Robert Novak; Rupesh Raina
Journal:  BMC Nephrol       Date:  2018-01-12       Impact factor: 2.388

8.  Acute Progression of Adult-Onset Atypical Hemolytic-Uremic Syndrome due to CFH Mutation: A Case Report.

Authors:  Bartlomiej Posnik; Dorota Sikorska; Krzysztof Hoppe; Krzysztof Schwermer; Krzysztof Pawlaczyk; Andrzej Oko
Journal:  Case Rep Nephrol       Date:  2013-02-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.